<DOC>
	<DOCNO>NCT01995058</DOCNO>
	<brief_summary>This study design evaluate safety efficacy combine abiraterone ( prednisone ) cabozantinib chemotherapy-naïve subject bone-metastatic castration-resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>Study Cabozantinib Combination With Abiraterone Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Must surgically medically castrate ( serum testosterone level less equal 50 ng/dL ) Must castrationresistant prostate cancer ( CRPC ) disease progression LHRH therapy surgical bilateral orchiectomy . Bone metastasis related prostate cancer Adequate organ marrow function Capable understand comply protocol requirement sign informed consent document Sexually active subject partner must agree use medically accept method barrier contraception ( eg , male condom female condom ) well one medically accept method contraception course study treatment 4 month last dose study treatment . Any prior treatment abiraterone , enzalutamide , investigational agent block androgen receptor ( AR ) androgen synthesis . Any prior treatment cabozantinib participation prior clinical trial cabozantinib . Any prior cytotoxic therapy ( include estramustine ) biologic therapy treatment prostate cancer ( exception allow ) Any prior radionuclide therapy ( eg , samarium 153 , strontium 89 , alpharadin ) Use investigational agent within 28 day Any pathological finding consistent small cell carcinoma prostate Known brain metastasis cranial epidural disease Diagnosis another malignancy within 2 year , except superficial nonmelanoma skin cancer , localize , low grade tumor deem cured treated systemic therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>CRPC</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>prostate cancer</keyword>
</DOC>